NUTRIBAND INC. DL -001
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops AVERSA b… Read more
NUTRIBAND INC. DL -001 (9WV) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, NUTRIBAND INC. DL -001 (9WV) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
NUTRIBAND INC. DL -001 - Net Assets Trend (None–None)
This chart illustrates how NUTRIBAND INC. DL -001's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for NUTRIBAND INC. DL -001 (None–None)
The table below shows the annual net assets of NUTRIBAND INC. DL -001 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to NUTRIBAND INC. DL -001's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
NUTRIBAND INC. DL -001 Competitors by Market Cap
The table below lists competitors of NUTRIBAND INC. DL -001 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Nordicus Partners Corporation
OTCQB:NORD
|
$12.27 Million |
|
FAR Limited
PINK:FARYF
|
$12.27 Million |
|
AmanahRaya Real Estate Investment Trust
KLSE:5127
|
$12.27 Million |
|
Westward Gold Inc
OTCQB:WGLIF
|
$12.28 Million |
|
AGX Group Berhad
KLSE:0299
|
$12.26 Million |
|
SIGMATRON INTL DL-01
F:SG3
|
$12.26 Million |
|
Oxford BioDynamics Plc
PINK:OXBOF
|
$12.26 Million |
|
Mount Ridley Mines Ltd
AU:MRD
|
$12.26 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in NUTRIBAND INC. DL -001's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares NUTRIBAND INC. DL -001's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently NUTRIBAND INC. DL -001 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares NUTRIBAND INC. DL -001's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| NUTRIBAND INC. DL -001 (9WV) | €- | N/A | N/A | $12.26 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |